A Multi-Center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxy Maltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Trial Profile

A Multi-Center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxy Maltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2015

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top